옵션 체인은 다양한 행사가격과 만기일에 대한 Saverone 2014의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Saverone 2014에 대한 시장 심리를 평가합니다..

Saverone 2014 (NASDAQ:SVRE) 주식, 옵션 체인

Saverone 2014

Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The Company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road, and pedestrians.

SaverOne 2014 Ltd. - American Depositary Shares

Saverone 2014 Ltd

Solana's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) has surged 21% over the past week, driven by excitement over meme coin launches and anticipation of <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43064882/bitcoin-etfs-outperform-in-first-year-but-solana-xrp-etfs-face-challenges-expert-says">a futures ETF</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$244.80</td>
<td>$119.1 billion</td>
<td>-4.6%&nbsp;</td>
<td>+21% </td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$3,208.51</td>
<td>$386.5 billion</td>
<td>-3.1%</td>
<td>-3.8%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$3.09</td>
<td>$177.7 billion</td>
<td>&nbsp;-2.6%&nbsp;</td>
<td> -2%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Jelle predicts "more violent moves" ahead as Solana consolidates near its previous all-time highs.
He <a href="https://x.com/CryptoJelleNL/status/1882367467336712584">views</a> the current correction as a healthy pause after its recent rally, suggesting, "It's only a matter of time before the next leg higher."
Meanwhile, trader IncomeSharks warns that Solana memes may face another dip, citing the importance of reclaiming the $272 level for a sustained bullish move.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SOL&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SOL</a> &#8211; Still making lower highs. Solana memes probably have another lower flush coming. Reclaim $272 and this is invalided <a href="https://t.co/8CkorAwqqL">pic.twitter.com/8CkorAwqqL</a>
&mdash; IncomeSharks (@IncomeSharks) <a href="https://twitter.com/IncomeSharks/status/1882199521423429954?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: According to DeFiLlama, Solana's total value locked (TVL) has hit a record $11.6 billion as of today. 
On-chain revenue has also peaked at $5.9 million.
Santiment <a href="https://x.com/santimentfeed/status/1882156632110485836">data</a> reveals mixed sentiment on Solana, with a 3:2 ratio of negative vs. positive comments across platforms like X, Reddit and Telegram. 
The network's minor decoupling from other altcoins, supported by meme coin activity, has stirred retail uncertainty amid transaction delays.  
Data shows whales and sharks are accumulating SOL even as retail traders reduce their holdings.
Community News: Bloomberg's Senior ETF Analyst Eric Balchunas <a href="https://x.com/EricBalchunas/status/1882155132219216240">shared</a> that Volatility Shares is leading the race to launch a Solana Futures ETF, potentially by mid-March. 
However, Balchunas remains uncertain about sustained demand, especially with a spot ETF anticipated soon.
SolanaFloor <a href="https://x.com/SolanaFloor/status/1882156348328337897">announced </a>that CME Group will launch SOL Futures contracts on Feb. 10.
Coinbase CEO Brian Armstrong <a href="https://x.com/brian_armstrong/status/1881987902701207678">assured</a> traders that the company is scaling infrastructure to better support Solana during periods of high demand, addressing delays in activities like DEX trading and meme coin transactions. 
He stated that their goal is to provide tier 1 support for Solana, comparable to Bitcoin, Ethereum and Base, which also faced delays recently due to high activity.
Armstrong oncluded, "The surge in activity is great for the ecosystem but we need to do a better job serving our customers during periods of high demand."
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43074520/solana-skyrockets-sees-15-surge-following-launch-of-trump-themed-meme-coin">Solana Skyrockets, Sees 15% Surge Following Launch Of Trump-Themed Meme Coin</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$ETH

$SOL

$XRP

Solana Jumps 20% In 7 Days: Why Is SOL Going Up?

WIIM

MarineMax shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) reported worse-than-expected fourth-quarter EPS and <a href="https://www.benzinga.com/news/earnings/25/01/43128325/ge-vernova-mixed-q4-revenue-misses-but-orders-surge-22-amid-strong-electrification-demand">revenue on Wednesday</a>.
The company reported revenue growth of 5% year-over-year to $10.559 billion and +9% organically, missing the consensus of $10.78 billion.
The company achieved orders totaling $13.2 billion, reflecting a 22% organic increase, ~1.3 times revenue, driven primarily by Power and Electrification equipment. Earnings per share for the quarter were $1.73, compared to $0.72 a year ago, missing the consensus of $2.55.
"GE Vernova built a strong foundation in 2024 with solid orders and revenue growth, as well as significant margin expansion and cash generation. We saw strength in Power and Electrification and improvement in Wind, while growing our equipment backlog at better margins," stated GE Vernova CEO Scott Strazik.
GE Vernova reaffirms its 2025 outlook with $36 billion – $37 billion in revenue versus a consensus of $36.88 billion, a high single-digit adjusted EBITDA margin, and $2 billion – $2.5 billion in free cash flow.
GE Vernova shares gained 2.7% to close at $427.10 on Wednesday.
These analysts made changes to their price targets on GE Vernova following earnings announcement.
<ul>
<li>JP Morgan analyst Mark Strouse maintained GE Vernova with an Overweight and raised the price target from $374 to $436.</li>
<li>Barclays analyst Julian Mitchell maintained the stock with an Overweight and raised the price target from $420 to $487.</li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-1024x489.png" alt="" class="wp-image-746761" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-1024x489.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174-768x367.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23081255/image-174.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

Earnings

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

GE Vernova Analysts Boost Their Forecasts After Strong Q4 Results

GE Aerospace CFO Says In 2025, Do Think Spare Parts To Stay Strong

EVTL

Vertical Aerospace shares are trading lower after the company announced a $90 million public offering.

Biotech

General

SELLAS Life Sciences Announces Interim Analysis For Phase 3 REGAL Trial Of GPS In Acute Myeloid Leukemia Showing; Says Independent Data Monitoring Committee Recommended Trial Continue Without Modifications

COEP

Coeptis Therapeutics Holdings Expands Its Technological Initiatives To Include Cutting-Edge Artificial Intelligence And Innovative Blockchain Solutions

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $6 price target.

Reiteration

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $6 Price Target

Data corroborate previously reported preclinical data demonstrating certepetide's ability to enhance the effectiveness of immunotherapy
Preliminary results to be presented at the 2025 ASCO Gastrointestinal Cancers Symposium
BASKING RIDGE, N.J. and SUBIACO, Australia, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and WARPNINE Incorporated ("WARPNINE"), Western Australia's first not-for-profit clinical research organization for pancreatic, gastro-intestinal and rare cancers, today announced encouraging preliminary results from the Phase 1b/2a iLSTA trial (<a href="https://www.globenewswire.com/Tracker?data=viG6Z8rb5yakmCziK5MC4KHIHD449o_0_iwBwzOnKLuIVX9ogOPIlIPp1gF8kKV4bkOsW4cHmYy5OZllI3q1fdfHwQ_EiqAKt0OJn1dwseNnLMKSutHtNTo4FzoF1DPTxQwyJFbH0lXRFKDo7QySmQ==">ACTRN12623000223639</a>) evaluating certepetide (formerly LSTA1), Lisata's proprietary investigational iRGD cyclic peptide product candidate, in combination with standard-of-care (SoC) chemotherapy and immunotherapy as a first-line treatment in locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The preliminary data will be presented in a poster session, entitled, "Immunotherapy combined with a novel iRGD peptide plus nab-paclitaxel and gemcitabine for locally advanced pancreatic ductal adenocarcinoma: A prospective study," at the 2025 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on Friday, January 24, 2025 at 11:30 a.m. - 1:00 p.m. (PST) in San Franscisco, California. For a detailed summary of the poster presentation, please see the abstract available on the ASCO GI website: <a href="https://www.globenewswire.com/Tracker?data=xhbTLxEjS_qv4xxw0rdbf9Rt0I_ukgclLSLtzTm27CY4aH8IsYbd4usSpVvBiLpC4lPd65aFQ8ovirYYzJtCon_gypsrzb3eZ8Am3EwukOPCVshYZxApc7bUzgoQWUApN9BvOUHo20-Tx0AxvGFbFPmy04pHaRoIuiyMBuEeQkZuPCIJxEmyVsPtYCxVjX4u">https://meetings.asco.org/abstracts-presentations/241611</a>
The Phase 1b/2a randomized, single-blind, single-center, safety and pharmacodynamic iLSTA trial, being conducted at St John of God Subiaco Hospital in Western Australia, a leading center for clinical research and innovation, is evaluating certepetide in combination with SoC chemotherapy (nab-paclitaxel and gemcitabine) plus SoC immunotherapy (durvalumab) versus SoC alone in patients with locally advanced non-resectable PDAC. This collaboration highlights the strength of combining global expertise with local excellence to address the urgent needs of patients with pancreatic cancer. Participants in the iLSTA trial were divided into three treatment cohorts (1:1:4 ratio): Cohort 1 (n=5) received SoC chemotherapy in combination with placebo durvalumab and placebo certepetide. Cohort 2 (n=5) received SoC chemotherapy plus certepetide and placebo durvalumab. Cohort 3 (n=20) received SoC chemotherapy plus durvalumab and certepetide. The preliminary results, representing an interim analysis of the first 17 of 30 targeted patients of the iLSTA trial are as follows:
Five of 16 patients evaluable by RECIST criteria experienced a partial response after 2 cycles of treatment (4 patients were in cohort 3), with the remaining 11 patients presenting with stable disease. After 4 cycles of treatment, 9 of 16 patients demonstrated partial response (8 patients were in cohort 3). Of the remaining 7 patients, 6 demonstrated stable disease, and 1 patient (cohort 2) exhibited a complete response. Fourteen of 17 patients who completed 4 treatment cycles showed a decrease in CA19-9 levels. Six patients demonstrated &gt;90% reduction in CA19-9 (5 of whom in cohort 3), with the remaining 8 patients showing a &gt;50% reduction in CA19-9 levels (6 of whom in cohort 3). Five patients had their repeat biopsies analyzed for tumor infiltrating lymphocytes (4 of whom from cohort 3), with all patients showing significant immune cell infiltration (15% to 50% stroma infiltration). These results demonstrate the potential value of adding certepetide to the SoC regimen consisting of gemcitabine, nab-paclitaxel, and durvalumab in this patient population.

LSTA

Lisata And WARPNINE Announces Interim Phase 1b/2a Results For Certepetide In Pancreatic Cancer; 56% Show Partial Response After 4 Cycles, With Up To 90% Reduction In CA19-9 Levels; Results To Be Presented At 2025 ASCO GI Symposium

Barclays analyst Jared Shaw maintains Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) with a Overweight and raises the price target from $151 to $155.

WTFC

Barclays Maintains Overweight on Wintrust Finl, Raises Price Target to $155

Carter Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARE#NASDAQ">CARE</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.24 by 54.17 percent. This is a 1950 percent increase over losses of $(0.02) per share from the same period last year.

CARE

Carter Bankshares Q4 Adj $0.37 Beats $0.24 Estimate

BANC

Bank of California shares are trading higher after the company reported better-than-expected Q4 EPS results.

ATXS

Astria Therapeutics Initiates Phase 1a Trial Of STAR-0310 For Treatment Of Atopic Dermatitis

Cass Information Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASS#NASDAQ">CASS</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.21 by 57.14 percent. This is a 45.9 percent decrease over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $50.37 million which beat the analyst consensus estimate of $49.48 million by 1.80 percent. This is a 0.72 percent decrease over sales of $50.74 million the same period last year.

CASS

Cass Information Sys Q4 EPS $0.33 Beats $0.21 Estimate, Sales $50.37M Beat $49.48M Estimate

Heritage Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFWA#NASDAQ">HFWA</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.45 by 13.33 percent. This is a 15.91 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $57.053 million which missed the analyst consensus estimate of $60.685 million by 5.98 percent. This is a 12.48 percent increase over sales of $50.724 million the same period last year.

Earnings Beats

Earnings Misses

HFWA

Heritage Financial Q4 2024 Adj. EPS $0.51 Beats $0.45 Estimate, Sales $57.053M Miss $60.685M Estimate

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">143.00</td>
<td align="right">0.82</td>
<td align="right">0.57</td>
<td>7.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">140.99</td>
<td align="right">0.74</td>
<td align="right">0.52</td>
<td>22.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">78.45</td>
<td align="right">0.13</td>
<td align="right">0.16</td>
<td>402</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.49</td>
<td align="right">0.08</td>
<td align="right">0.15</td>
<td>56.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.11</td>
<td align="right">0.01</td>
<td align="right">0.02</td>
<td>478</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">239.73</td>
<td align="right">-1.66</td>
<td align="right">-0.69</td>
<td>12.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">98.71</td>
<td align="right">-0.54</td>
<td align="right">-0.55</td>
<td>1.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">229.38</td>
<td align="right">-0.65</td>
<td align="right">-0.29</td>
<td>415</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">77.18</td>
<td align="right">-0.04</td>
<td align="right">-0.06</td>
<td>1.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">88.72</td>
<td align="right">-0.02</td>
<td align="right">-0.03</td>
<td>653</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For January 23, 2025

Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) reported quarterly adjusted earnings of $0.31 per share which beat the analyst consensus estimate of $0.22 by 40.91 percent. This is a 14.81 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $5.72 billion which missed the analyst consensus estimate of $5.99 billion by 4.51 percent. This is a 3.13 percent decrease over sales of $5.91 billion the same period last year.

Freeport-McMoRan Q4 Adj $0.31 Beats $0.22 Estimate, Sales $5.72B Miss $5.99B Estimate

Barclays analyst Alex Scott maintains Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) with a Equal-Weight and raises the price target from $127 to $128.

Barclays Maintains Equal-Weight on Prudential Financial, Raises Price Target to $128

LiveOne Surpasses 600,000 Tesla Users, Says 275,000 Are Ad-Supported Users

Barclays analyst Lauren Lieberman maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Equal-Weight and raises the price target from $155 to $159.

Barclays Maintains Equal-Weight on Procter & Gamble, Raises Price Target to $159

SaverOne 2014 Ltd. ADR (SVRE) has released an update. SaverOne 2014 Ltd. has initiated a pilot project with Trans Italia, a leading logistics compa...

SaverOne Partners with Trans Italia for Safety Pilot

SaverOne 2014 Ltd. ADR ( ($SVRE) ) has issued an update. SaverOne 2014 Ltd. has announced an Extraordinary General Meeting of Shareholders to be he...

SaverOne 2014 Ltd. Announces Key Shareholder Meeting for Strategic Proposals

The latest announcement is out from SaverOne 2014 Ltd. ADR ( ($SVRE) ). SaverOne 2014 Ltd. has entered a new distribution agreement with Smartfits ...

SaverOne Expands into UK Market with Smartfits Partnership

SaverOne announces distribution agreement with Smartfits in the UK

SaverOne 2014 (SVRE) announces an expansion of its deployment within another division of a global food manufacturer's subsidiary in Israel. This fo...

SaverOne 2014 announces expansion of deployment of drive safety solutions

An announcement from SaverOne 2014 Ltd. ADR ( ($SVRE) ) is now available. SaverOne has announced the expansion of its driver safety solutions withi...

SaverOne Expands Safety Solutions in Global Food Manufacturer's Fleet

SaverOne 2014 (SVRE) announced the award by the United States Patent and Trademark Office of a new patent. The patent, bearing the number 12,174,30...

SaverOne 2014 granted U.S. patent for transportation safety solution

SaverOne 2014 Ltd. ADR ( ($SVRE) ) has issued an announcement. SaverOne has been granted a new US patent for its innovative phone location identifi...

SaverOne Strengthens IP with New US Patent for Driver Safety Technology

SaverOne 2014 Ltd. ADR ( ($SVRE) ) has shared an announcement. SaverOne 2014 Ltd. has announced an Extraordinary General Meeting of Shareholders sc...

SaverOne 2014 Ltd. Calls Extraordinary Meeting to Vote on Key Corporate Changes

SaverOne 2014 Ltd. ADR ( ($SVRE) ) has shared an update. SaverOne 2014 Ltd. announced a new distribution agreement with uniSmart Vertriebs GmbH in ...

Comments

Saverone 2014

Saverone 2014 (SVRE) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌